Prab: CSV import

2025-02-18T04:58:10Z

CSV import

← Older revision		Revision as of 04:58, 18 February 2025
Line 16:		Line 16:
	{{antiparkinson agents}}		{{antiparkinson agents}}
	{{coststubd}}		{{coststubd}}
			== Tolcapone ==
			<gallery>
			File:Tolcapone.svg\|Chemical structure of Tolcapone
			File:Tolcapone3d.png\|3D model of Tolcapone
			File:3s68_tcw.png\|Tolcapone bound to COMT enzyme
			File:COMT_activity.svg\|COMT enzyme activity
			File:Tolcapone_metabolism.svg\|Metabolism of Tolcapone
			File:Tolcapone_synthesis.svg\|Synthesis of Tolcapone
			</gallery>

Prab: Created page with "{{intro}} Entacapone is a catechol-O-methyltransferase inhibitor used in the therapy of Parkinson disease as adjunctive therapy in combination with levodopa and carbidopa...."

2019-05-02T15:54:50Z

Created page with "{{intro}} Entacapone is a catechol-O-methyltransferase inhibitor used in the therapy of Parkinson disease as adjunctive therapy in combination with levodopa and carbidopa...."

New page

{{intro}}
Entacapone is a catechol-O-methyltransferase inhibitor used in the therapy of [[Parkinson disease]] as adjunctive therapy in combination with levodopa and carbidopa. Entacapone has been associated with a low rate of serum enzyme elevations during treatment, but has yet to be implicated in cases of clinically apparent acute liver injury with jaundice.
{{livtox}}

{{moa}}
Entacapone (en tak' a pone) is a specific inhibitor of cathechol-O-methyltransferase (COMT) which is a major enzyme in the pathway of levodopa metabolism. As a result, entacapone slows the metabolism of levodopa, causing an increase in its bioavailability and duration of action. Entacapone inhibits COMT activity only peripherally, unlike tolcapone which acts both peripherally and centrally.

{{fda}}
Entacapone was approved for use in the United States in 2003, the second COMT inhibitor approved for use in the therapy of symptomatic [[Parkinson disease]] as an adjunct to levodopa/carbidopa therapy in patients with motor complications.

{[dose}}
Entacapone is available in tablets of 200 mg generically and under the brand name of Comtan. It is also available in several fixed dose combinations with carbidopa and levodopa generically and under the brand name Stalevo. Entacapone is typically initiated in doses of 200 mg with each dose of levodopa/carbidopa to a maximum of 1600 mg daily.

{{se}}
Common side effects include somnolence, dizziness, [[confusion]], dyskinesia, vivid dreams, hallucinations, depression, fatigue, headache, diarrhea and gastrointestinal upset, side effects that are largely due to enhancement of the dopaminergic effects of levodopa.
{{antiparkinson agents}}
{{coststubd}}

Tolcapone - Revision history

Prab: CSV import

Prab: Created page with "{{intro}} Entacapone is a catechol-O-methyltransferase inhibitor used in the therapy of Parkinson disease as adjunctive therapy in combination with levodopa and carbidopa...."